跳至主要内容
临床试验/JPRN-UMIN000053556
JPRN-UMIN000053556尚未招募Unknown

Monitoring the Efficacy of Tafamidis in ATTR Cardiac Amyloidosis by MRI-ECV: A Systematic Review and Meta-Analysis - Monitoring the Efficacy of Tafamidis in ATTR Cardiac Amyloidosis by MRI-ECV: A Systematic Review and Meta-Analysis

Yokohama City University0 个研究点开始时间: 2024年2月6日最近更新:
适应症

试验速览

阶段
Unknown
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Other

入排标准

年龄范围
18years-old 至 90years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • Search Strategy and Selection Criteria Following the methodology proposed by the Cochrane Collaboration and adhering to the reporting criteria outlined in the 2020 Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) guidelines, we conducted a comprehensive database search using PubMed, Web of Science Core Collection, Cochrane advanced search, and EMBASE electronic databases. Use the following keywords: "tafamidis", "extracellular volume fraction", "extracellular volume", "ECV", "MRI", "cardiac MRI". Eligibility criteria present pre- and post-treatment MRI-ECV values for tafamidis and encompass all articles discoverable with the specified keywords. Exclusion criteria will be limited to case reports, animal studies, and non-English language articles.

研究者

相似试验